nFusz CEO Rory Cutaia Tells How He Made People

New Post Public Reply Private Reply Replies (0) Message Board
SHEEPWOLF
267
nFusz CEO Rory Cutaia Tells How He Made People Millionaires, and Will Do It Again, on iHeart Radio

Rory Cutaia Talks with Michael Yorba on CEO Money on Talk Radio 1190
DALLAS, TX - December 1, 2017 -- nFusz, Inc. (FUSZ) CEO Rory J. Cutaia told iHeart Radio listeners yesterday how he made investors, company members and employees millionaires when he sold his last company, and how he’s planning to do it all over again with nFusz. The Chief Executive Officer talked candidly with host Michael Yorba on CEO Money, iHeart’s Talk Radio 1190 AM Dallas/Fort Worth, about how he is now disrupting the $38 billion CRM industry.
A video from the segment, accompanying this press release is available here.
“I started my career at a prominent law firm, representing some of the top entrepreneurs the world has ever produced. I consider myself a recovering lawyer,” said nFusz CEO Rory J. Cutaia. “I left the legal profession to become an entrepreneur myself, and founded a company called Telx, which created the defacto standard for the telecom industry, called colocation. I sold that company for $200M, our investors received more than eighteen times their invested capital, I made a lot of millionaires in the company, distributed stock to all the employees and even the receptionist was able to purchase a home and change her life. Telx is a great company, in fact it was recently sold again, about a year ago, for almost $2 billion,” said Mr. Cutaia.
Now Mr. Cutaia is taking on the $38 billion CRM industry with nFusz’s flagship product, notifiCRM, which was launched in September of this year. The software product is on the watch list for Sales Force, NetSuite and other CRM giants. While other CRM companies focus on tracking engagement, notifiCRM creates it, using interactive video with clickable calls-to-action right in the video. Users can send succinct, effective, corporate compliant and interactive videos through email, SMS messages, or on social media.
notifiCRM allows anyone to become a video marketing and sales expert, starting at just $9.95/month, plus a modest one-time activation fee. Users learn exactly how video recipients are behaving and responding, right in the system. It is the only platform that offers users analytics on who watched a video, how many times, for how long, and which calls to action were engaged. The user can easily, visually identify who are the most interested prospects, and re- target them, right through the system. Calls to action can include: purchasing a product, initiating a phone call or email, launching or auto-launching a website, or scheduling an appointment, all without leaving the original interactive video.
Most people today, can’t sell. Our product removes selling skills out of the sales process by using proprietary, interactive video technology with corresponding analytics,” said Mr. Cutaia. “In today’s video-centric world, if you’re not using video to market yourself, you’re easily ignored. If you want to be effective, you must deliver messaging in a way that is engaging and succinct, while empowering the user to act on-demand, seamlessly. The only way to achieve this is through video, and not just video, interactive video. That’s the solution, and customers are seeing increased conversion rates by up to 600%,” continued Cutaia.
nFusz CEO Rory J. Cutaia will be a regular guest on IHeart’s Talk Radio 1190 AM Dallas/Fort Worth, every Wednesday at 12pm PT/3pm ET.

https://nfusz.com/wp-content/uploads/2018/01/...3017v2.pdf

TON Strategy Co. (TONX) Stock Research Links

TONX Board Company Profile Buy Rating Time & Sales News Filings Financials
Sojourner here following God, obeying God, and cleaving to Him. The journey is onward.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sarepta Under Scrutiny: KSF's Investigation Deepens

Updated Category News Views 3

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Continue Reading
Cyngn: A Deep Dive into Its Robust 24-Patent Portfolio

Updated Category News Views 4

Cyngn's Growing Patent Portfolio: A Robust Defense Ah, Cyngn Inc., the hotshot in AI-powered autonomous vehicle tech, is flexing its muscles with a solid 24-patent stash. We're talking about a company that's not messing around, racking these up since they decided to dive head-first into solving the brain-busting problems of the industrial sector. Their strategy? Build and...

Continue Reading
New Concierge Pediatric Care at Weill Cornell Launches

Updated Category News Views 3

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Continue Reading
Postal Service Defends New Rule Amid Speculation

Updated Category News Views 3

USPS Navigates Election Mail Controversies The U.S. Postal Service has found itself in the eye of a political storm, thanks to the latest Federal Ballot Mail Rule. Led by Postmaster General David Steiner, the USPS is setting the record straight amidst swirling misinformation and skepticism about its recent actions. This is not just a postal service under scrutiny—it's a...

Continue Reading
Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Updated Category News Views 6

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Continue Reading
BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

Updated Category News Views 1

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Continue Reading
S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Updated Category News Views 5

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

Continue Reading
TrailBlazer Magazine Snags a Tribune for In-House Design

Updated Category News Views 4

Who Knew? Design Awards Aren't Just for Pretty Pictures TrailBlazer Magazine gets a pat on the back from GDUSA's 2026 Inhouse Design Awards, a nod to top-notch design work. With over 4,000 entries across the board, getting into the top 10 percent is like finding a steakhouse with zero line on a Friday night. Not exactly common, right? Design Worth Cheering For The winning...

Continue Reading
MMRO Achieves URAC AI Accreditation, Ensures Compliance

Updated Category News Views 4

A Milestone in Healthcare AI: MMRO's New Accreditation When AI in healthcare gets an official nod from the big guys like URAC, it's a significant moment. We're talking about Managed Medical Review Organization, Inc. (MMRO), a firm that's just earned the URAC Artificial Intelligence in Health Care Accreditation. Now, this isn't just some rubber stamp; it's a testament to...

Continue Reading
Dimerix Locks Down A$34M Loan: No Shareholder Dilution

Updated Category News Views 2

Dimerix Grabs Non-Dilutive Funds amid Kidney Trials Here we go with Dimerix's latest move, folks. They roped in A$34 million through a cozy get-together with lenders from Australia and the U.S. What's the kicker? This cash won't touch shareholder equity. So, breathe easy, investors. It's a rare feat to pull off non-dilutive funds these days, especially in the biopharma...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming the Narcolepsy Market: Innovations Ahead

Updated Category News Views 166

The Evolving Landscape of the Narcolepsy Market The narcolepsy market is undergoing significant changes as it shifts from merely managing symptoms to developing targeted therapies that tackle the root causes of the disorder. Traditionally, treatments focused on alleviating symptoms, but advancements now emphasize addressing the underlying neurochemical issues, primarily...

Continue Reading
UBS Analysts Share Insights on China Stocks Strategies

Updated Category News Views 242

UBS Analysts Offer Insights on China's Equity Market In a recent discussion, UBS strategists have expressed a level of caution regarding China's equity market as they look into the evolving landscape of 2025. It's noted that local A-share investors appear hesitant to seize buying opportunities, influenced by a myriad of factors that create uncertainty in the market....

Continue Reading
Palisade Bio's Special Meeting Cancellation: What You Need to Know

Updated Category News Views 133

Palisade Bio Cancels Special Meeting of Stockholders Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company making strides in developing innovative treatments for autoimmune, inflammatory, and fibrotic diseases. Recently, the company announced an important decision regarding its special meeting of stockholders. The special meeting, originally...

Continue Reading
Vivendi Reports Impressive 4.5% Revenue Growth in 2024

Updated Category News Views 123

Remarkable Revenue Growth for Vivendi Vivendi has announced an impressive increase in its revenues for the first nine months of 2024, emphasizing strong growth across its core business sectors. The company reported a revenue increase of 4.5% at constant currency and perimeter, compared to the same period in the previous year. This growth showcases the resilience and...

Continue Reading
Revolution in Home Renovation Arrives with Spray-Net Franchise

Updated Category News Views 226

Fresh Approach to Home Makeovers Home remodeling isn’t just about slapping on a new coat of paint anymore. In February 2026, Spray-Net is gearing up to launch in Allen, Texas, shaking things up in the renovation game. This venture represents a leap forward—not only for franchise growth but for homeowners who are sick and tired of traditional, drawn-out renovations....

Continue Reading